key: cord-0866094-hki0xhwc
authors: Paramasivam, Arumugam; Priyadharsini, Jayaseelan Vijayashree; Raghunandhakumar, Subramanian; Elumalai, Perumal
title: A novel COVID-19 and its effects on cardiovascular disease
date: 2020-04-30
journal: Hypertens Res
DOI: 10.1038/s41440-020-0461-x
sha: ed8030cfd05994772be5689ee6e3b8439c630ed8
doc_id: 866094
cord_uid: hki0xhwc

nan

Coronavirus disease (COVID-19) is a novel infectious disease caused by a newly discovered severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) [1, 2] . COVID-19 spread rapidly from China, reaching a pandemic and putting the world on alert. SARS-CoV-2 has been reported in 211 countries, areas or territories, and >1,200,000 cases have been confirmed, with an estimated mortality risk of~5.5% (https://www.who.int/emergencies/diseases/novel-corona virus-2019). In India,~5000 patients were confirmed with SARS-CoV-2, with an estimated mortality risk of~2.5% and an escalating incidence rate increasing daily. Unfortunately, there are no specific vaccines or treatments for COVID-19 at this time, and current management includes travel restrictions, patient isolation, and supportive medical care. However, scientists are endeavoring to discover drugs and vaccines for COVID-19, but a better understanding of the underlying pathobiology is required.

More recent research has suggested that older people and people with chronic health conditions, including cardiovascular disease (CVD), are at higher risk for mortality and morbidity related to COVID-19 than the average population [2] . In a case series of 21 patients with COVID-19, congestive heart failure was the second most common baseline comorbidity (42.9%) [3] . A new study reported that COVID-19 can cause heart injury, even in people without underlying heart issues [2] . However, while the clinical manifestations of COVID-19 are dominated by respiratory symptoms, cardiovascular involvement can occur through several other mechanisms [4] . Acute cardiac injury is the most frequently reported cardiovascular abnormality in COVID-19, and it occurs in~8-12% of all patients [5] . The presence of underlying CVD and/or development of acute cardiac injury might confer an increased risk of death (Table 1) .

A recent study reported the importance of cardiac injury in patients with COVID-19; in these patients, 10.6% had coronary heart disease, 4.1% had heart failure, and 5.3% had cerebrovascular disease. Approximately 20% of patients had cardiac injury. A similar study demonstrated factors associated with outcomes in 187 patients with COVID-19. They showed that 35% had underlying CVD (hypertension, coronary heart disease, or cardiomyopathy), and 28% showed evidence of acute myocardial injury (defined as elevated troponin T). Furthermore, mortality was significantly higher in individuals with high troponin T levels than in those with normal troponin T levels. In addition, patients with high troponin T levels were older and had more comorbidities, including hypertension, coronary heart disease, cardiomyopathy, and chronic kidney disease [2] .

Another study showed that the incidence of acute heart failure was 23% (44 out of 191 patients with COVID-19) and that multiple precipitating etiologies, including acute coronary syndrome, cardiac arrhythmias, stress-induced cardiomyopathy, and fulminant myocarditis, might result in acute heart failure or cardiogenic shock in patients with COVID-19 [6] . Lactate dehydrogenase (LDH), creatine kinase (CK) and their isoenzymes as well as the protein troponin I (TnI), which exhibited better cardiac specificity, are linked with injury of the heart muscle. Chen [9] . Although SARS-CoV-2 potentially invades alveolar epithelial cells, resulting in an acute systemic inflammatory response [4, 6] , the exact etiology and mechanisms of elevation of cardiac biomarkers among patients with COVID- 19 have not yet been reported. The identification of angiotensin-converting enzyme 2 (ACE2) as a functional receptor for coronaviruses, including SARS-CoV and SARS-CoV-2, provides clues about their indirect association with cardiovascular pathology. The ACE2 receptor, the binding point for SARS-CoV-2, is abundantly found in myocytes. Therefore, myocyte damage from a direct viral attack could very well be the predominant mechanism.

ACE2 is a membrane-bound aminopeptidase that is highly expressed in the heart and lungs, and has a vital role in the cardiovascular and immune systems in normal health as well as in various disease conditions [1, 10] . ACE2 is also involved in heart function and the development of hypertension and diabetes mellitus. The binding of SARS-CoV-2 to ACE2 can result in alteration of ACE2 signaling pathways, leading to acute myocardial and lung injury. COVID-19 is more severe in patients with CVD, which might be associated with increased secretion of ACE2 in these patients compared with healthy individuals [1, 10] .

In conclusion, there seems to be a unique interplay between SARS-CoV-2 and CVDs. Although COVID-19 is predominantly a respiratory illness, a large number of patients with COVID-19 present with preexisting CVD or develop new-onset cardiac dysfunction during the course of the illness. Therefore, understanding the CVD caused by SARS-CoV-2 and the underlying mechanisms is of the greatest importance, and during treatment for COVID-19, careful attention should be given to cardiovascular protection.

Conflict of interest The authors declare that they have no conflicts of interest.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Heart failure 52% in those who died and 12% in those who recovered [6] Acute cardiac injury 59% in those who died and 1% in those who recovered [6] Arrhythmia 16.7% [8] Acute cardiac injury 7.2% [8] 

Antihypertensive treatment with ACEI/ ARB of patients with COVID-19 complicated by hypertension

Potential effects of coronaviruses on the cardiovascular system: a review

Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Laboratory abnormalities in patients with COVID-2019 infection

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan

China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses